InsidersTradesSigma
Follow the CELLECTIS share price and the full directors' dealings record of the company, a listed issuer based in France. Shares are quoted on the FR market, under the oversight of AMF. Operating in the Healthcare & Pharma sector, CELLECTIS has logged 27 public disclosures. Market capitalisation: €232.6m. The latest transaction was disclosed on 4 June 2026 (Cession). Among the most active insiders: David Sourdive. The full history is openly available.
27
Insider Decl.
n/a
Thresholds
€109,200
1 ops.
Buy Volume
€4m
10 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CELLECTIS Strong Buy (bullish), based on 1 analysts. Average price target: €6.50.
61Σ signal
Fundamental score
Ranked 26,132 of 29,055 companies
21.9
score / 100
Value12
Quality32
FCF yld-14%
Earn yld-22%
EV/EBITDA·
ROE-95%
Gross mgn87%
Net mgn-93%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 June 2026
Declarations27 total
500,000 shares@ €2.590.40% mcap50.0% of flowActionEuronext Growth ParisISIN FR00104255952026DD1118287
33,630 shares@ €3.14220.033% mcap50.0% of flowActionEuronext Growth ParisISIN FR00104255952026DD1118290
5,875 shares@ €3.050.0056% mcap3.8% of flowActionEuronext Growth ParisISIN FR00104255952026DD1117956
50,000 shares@ €3.15050.049% mcap34.6% of flowActionEuronext Growth ParisISIN FR00104255952026DD1117648
32,042 shares@ €3.13020.031% mcap22.0% of flowActionEuronext Growth ParisISIN FR00104255952026DD1117649
62,083 shares@ €3.1740.062% mcap43.3% of flowActionEuronext Growth ParisISIN FR00104255952026DD1117647
500,000 shares@ €2.590.40% mcap100.0% of flowActionEuronext Growth ParisISIN FR00104255952026DD1117614
88,650 shares@ €3.06590.085% mcap2.2% of flowActionEuronext ParisISIN FR00104255952026DD1116310
70,000 shares@ €1.560.034% mcap0.9% of flowActionEuronext ParisISIN FR00104255952026DD1116313
Canonical exit: 19 Aug 2026 (T+90)
00ActionEuronext ParisISIN FR00104255952026DD1116025
33,630 shares@ €3.14220.033% mcap100.0% of flowActionEuronext Growth ParisISIN FR00104255952026DD1115976
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104432
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104439
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104421
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104422
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104423
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104425
Canonical exit: 22 Aug 2025 (T+90)
1,060 shares0ActionHors plateforme de négociationISIN FR00104255952026DD1104427
Canonical exit: 22 Aug 2025 (T+90)
9,010 shares@ €1,312.0096.9% of flowActionHors plateforme de négociationISIN FR00104255952025DD1025103
9,010 shares@ €1,312.00100.0% of flowActionHors plateforme de négociationISIN FR00104255952025DD1025114
9,010 shares@ €1,312.00100.0% of flowActionHors plateforme de négociationISIN FR00104255952025DD1025095
9,010 shares0ActionHors plateforme de négociationISIN FR00104255952025DD1024806
9,010 shares0ActionHors plateforme de négociationISIN FR00104255952025DD1024768
9,010 shares0ActionHors plateforme de négociationISIN FR00104255952025DD1024772
9,010 shares0ActionHors plateforme de négociationISIN FR00104255952025DD1024801
25 of 27 declarations
关于 CELLECTIS
Cellectis 是一家临床阶段的生物技术公司，专注于基因编辑和开发创新的癌症免疫疗法。公司成立于 25 年前，其科学基础围绕两项专有技术构建：其旗舰基因编辑平台 TALEN® 和电穿孔系统 PulseAgile。这些技术支持下一代细胞和基因疗法的设计，重点关注安全性、有效性和生产可扩展性。 Cellectis 业务的核心是开发现成的同种异体候选产品，特别是基因编辑的 CAR-T 疗法，旨在为患者提供即用型治疗。公司主要针对高度未满足需求的血液系统癌症，包括 B 细胞急性淋巴细胞白血病 (B-ALL) 和非霍奇金淋巴瘤。其产品线包括多个 UCART 项目，旨在为个性化自体方法提供一种可能更具工业化潜力的替代方案。 从市场定位的角度来看，Cellectis 是欧洲将基因编辑应用于肿瘤学的先驱之一。其在 TALEN® 方面的长期专业知识提供了精确细胞工程方面的差异化能力，这在一个由主要制药和生物技术公司主导的高度竞争的领域中具有战略价值。公司通过内部开发以及科学和工业合作（包括与主要医疗保健集团的合作）来开发项目，以加速研究并分担开发风险。 Cellectis 总部位于巴黎，并在纽约和罗利设有运营机构，反映了其跨大西洋的业务足迹，支持研究、开发和投资者关系。公司在泛欧交易所增长市场上市，代码为 ALCLS，在纳斯达克上市，代码为 CLLS。其在 2026 年春季发布的最新公开财务更新证实了多个 1 期和 2 期临床研究的进展，以及正在进行的战略合作，突显了以颠覆性创新和其基因编辑平台的价值创造潜力为核心的长期战略。
